Dermatology News and Research

Latest Dermatology News and Research

NEJM hails vismodegib as ‘the greatest advance in therapy yet seen’ for advanced BCC

Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.

14 Jun 2012

Initial trial results from KYTHERA’s second of two Phase III trials with ATX-101

KYTHERA Biopharmaceuticals, Inc. today announced the presentation of initial trial results from Study ATX-101-10-17, the second of two pivotal European Phase III clinical trials with ATX-101, a facial injectable drug for the aesthetic treatment of submental fat, which commonly presents as an undesirable double chin.

12 Jun 2012

ACE program can help hospitals lower health care costs

Creating specialized hospital units for elderly people with acute medical illness could reduce national health care costs by as much $6 billion a year, according to a new study by UCSF researchers.

11 Jun 2012

JCAD publishes results from clincal study of Tria Skin Perfecting Blue Light for acne

The Journal of Clinical and Aesthetic Dermatology (JCAD), a respected peer-reviewed dermatology publication, has, in its May 2012 issue, published the results of a single-center study of the Tria Skin Perfecting Blue Light for acne, showcasing the overall effectiveness of the device in significantly reducing the amount of acne, as well as the frequency, severity and redness of acne flares.

10 Jun 2012

Steroids may slow progression of life-threatening skin reactions

Multi-national study results show that the progression of Steven Johnson Syndrome or Toxic Epidermal Necrolysis may be lengthened if corticosteroids are used prior to the onset of either condition.

8 Jun 2012

Promising results for dabrafenib in advanced melanoma

The BRAF inhibitor dabrafenib shows promising results for treatment of advanced melanoma, both alone and in combination with the MEK inhibitor trametinib, show results from two studies presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.

8 Jun 2012

Psoriasis link with autoimmune diseases underscored

Patients with psoriasis are nearly twice as likely to have an autoimmune disease as individuals without the condition, suggest study findings.

8 Jun 2012

Hypocaloric diet may help achieve minimal disease activity in psoriatic arthritis patients

According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with psoriatic arthritis (PsA) who are starting anti-tumour necrosis factor (anti-TNF) treatment and adhere to a hypocaloric diet have a significantly greater chance of achieving minimal disease activity (MDA, an important measure of disease activity) at six months compared to those on a standard diet.

8 Jun 2012

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

Patients with active psoriatic arthritis receiving the interleukin (IL)-12/23 inhibitor STELARA (ustekinumab) experienced significant improvements in signs and symptoms of the disease, according to new findings presented today from a Janssen Research & Development, LLC, (Janssen)-sponsored investigational study.

6 Jun 2012

Jennerex announces data from JX-594 clinical studies on cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer was featured in three separate abstracts during the American Society of Clinical Oncology (ASCO) Annual Meeting currently taking place in Chicago, Illinois.

5 Jun 2012

Imiquimod and PDT equivalent for superficial basal cell carcinoma

Imiquimod cream and photodynamic therapy for superficial basal cell carcinoma result in near equivalent rates of tumor-free survival after 1 year of treatment, a review shows.

1 Jun 2012

Psoriasis linked to sexual dysfunction in men

Men with psoriasis are at an increased risk for sexual dysfunction, research suggests.

1 Jun 2012

Common pain killers linked to decreased skin cancer risk

Use of nonsteroidal anti-inflammatory drugs is associated with a decreased risk for skin cancer, particularly squamous cell carcinoma and malignant melanoma, study findings indicate.

31 May 2012

Researchers identify new peptide that can block fibrosis of the skin and lungs

A member of the Scleroderma Foundation's Board of Directors has led a team of researchers who have identified a peptide that can block fibrosis of the skin and lungs, according to a report published today.

31 May 2012

Skin transplant surgery safe and effective for patients with vitligo

Henry Ford Hospital dermatologists say skin transplant surgery is safe and effective for restoring skin pigmentation caused by the skin disease vitligo.

31 May 2012

Stiefel to acquire WBI-1001 licensing rights from Welichem

Stiefel, a GSK company, and Welichem Biotech Inc., have entered into an agreement for the acquisition by Stiefel of exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories in the world outside of China, Taiwan, Macao and Hong Kong.

31 May 2012

Intensive exercise answer to psoriasis prevention

Vigorous physical activity may reduce a person’s risk for developing psoriasis, show results from a US study.

30 May 2012

Intensity of itching in eczema linked to depression

Itch intensity in atopic dermatitis is related to the stress level and emotional wellbeing of patients, say researchers.

30 May 2012

FDA approves RLI’s Absorica to treat severe recalcitrant nodular acne

Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica, a novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne.

30 May 2012

FDA approves Cipher’s Absorica to treat severe recalcitrant nodular acne

Cipher Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica, Cipher's novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne.

28 May 2012